Safety and Efficacy of Grazoprevir and Elbasvir for GT1ang GT6 With and Without HIV
Status:
Active, not recruiting
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and efficacy of combination treatment with grazoprevir +
elbasvir for compensated cirrhotic participants with chronic genotype 1 (GT1) and genotype 6
(GT6) hepatitis C virus (HCV) infection with or without human immunodeficiency virus (HIV)
infection.
Phase:
Phase 4
Details
Lead Sponsor:
The HIV Netherlands Australia Thailand Research Collaboration
Collaborators:
Chulalongkorn University Merck Sharp & Dohme Corp.